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Since the mid-1950s the pharmaceutical industry has developed a number of chemicals, including phencyclidine,
ketamine and related arylcyclohexylamines (PCE and TCP), dizocilpine (MK-801), N-allylnormetazocine
[ NANM, (&plusmn;)SKF-10,047], etoxadrol, dioxadrol and its enantiomers dexoxadrol and levoxadrol, which produce
a constellation of unusual behavioral effects in animals and man. The compounds best studied in humans
are phencyclidine and ketamine. They produce a remarkable dose-dependent dissociation of awareness. All
of these substances are now known to be non-competitive antagonists of NMDA receptors of glutamic acid.
They act in the NMDA receptor ion channel. One can conclude, on the basis of the effects observed with these
agents, that glutamic acid and related excitatory amino acids are extremely important in the maintenance
of human awareness.
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Introduction
There are many chemical substances that, when taken by
humans, increase, decrease or dramatically alter aware-
ness. Consciousness has many components including
awareness of the external environment, one’s body image,
concept of self and identity. Alertness can easily be
distinguished from natural sleep, dreaming, stupor,
general anesthesia and coma. Many chemicals and drugs
alter consciousness, affecting subjective awareness and
experience. They alter brain responses to sensory inputs
from the external and internal environment. Almost all
chemicals or drugs which act on the brain alter levels of
awareness. These include drugs of abuse as well as socially
approved or tolerated substances such as ethyl alcohol,
caffeine, nicotine and medications such as narcotics and
psychotropics. Alteration of awareness by chemical
means has been practiced by every human culture since
man’s earliest recorded beginnings. The concept of the
dose of the substance taken is crucial. For example,
depending on dose, d-amphetamine may increase aware-
ness or alter it dramatically, leading to frank psychosis.
An interesting means of chemical dissociation of
awareness is through the use of substances which alter
the function of the NMDA receptor of the excitatory
amino acid neurotransmitter, glutamic acid. There are
many substances which either increase or decrease the
functional state of this glutamatergic synapse and, hence,
dramatically alter awareness. The present communication
summarizes our current knowledge of the different
chemicals which alter NMDA receptor function by
blocking its ion channel and thus altering human
awareness. The substances selected for review have all
been given to humans, but some have been inadequately
studied in man.
Phencyclidine
Phencyclidine was first given to humans in the late 1950s.
It was initially studied as an intravenous anesthetic
(Greifenstein et al., 1958; Johnstone, Evans and Baigel,
1959), and later as a chemical model of sensory
deprivation (Meyer, Greifenstein and DeVault, 1959) and
schizophrenia (Luby et al., 1959, 1962; Cohen et al., 1959)
well before its primary mechanism of action was
determined to be that of a non-competitive NMDA
receptor antagonist.
The history of phencyclidine and related arylcyclo-
hexylamines was described by a number of the early
investigators. It has been documented from the point of
view of a medicinal chemist (Maddox, 1981), neuro-
pharmacologist (Chen, 1981; McCarthy, 1981) and a
psychiatrist (Luby, 1981). Domino and Luby (1981)
compared some of the symptoms of schizophrenia with
those induced by phencyclidine, sensory isolation, sleep
deprivation and LSD-25. Their summary table is
reproduced as Table 1. It is very clear that none of the
models of schizophrenia mimic precisely the symptoms
of the natural disease, but phencyclidine seems to be a
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Table 1 Comparison of various symptoms of schizophrenia with those induced by
phencyclidine, sensory isolation, sleep deprivation and LSD-25
From Domino and Luby, 1981
better model than the others. Luby et al. (1959) and
Cohen et al. (1959) gave the drug as an i.v. infusion in
a dose of 0.1 mg/kg in 150 ml in 5 % glucose. Normal
volunteers showed five major psychological changes
including:
1. most commonly loss of ego boundaries;
2. intellectual impairment;
3. induction of affectively charged personal experiences;
4. a pervasive sense of isolation;
5. fluctuations in the psychological environment with
feelings of being in past settings with a lack of time
boundedness.
A few drug-free schizophrenic patients given phen-
cyclidine generally became more assertive, hostile and
unmanageable, with behavioral changes lasting for
approximately 1 month. This was in contrast to the short-
lasting effects in the normal volunteers. One catatonic
patient became worse directly after receiving phen-
cyclidine, but 4 days later emerged from his stuporous
state. He remembered his strange experience with
phencyclidine and maintained a behavioral improvement
for ~ 1.5 months.
Two other phencyclidine derivatives, N ethyl-1-
phenylcyclohexamine (CI-400, PCE) and 1- [ 1-(2-thienyl)
cyclohexyl] piperidine (CI-421, TCP), were also tested
in humans as i.v. anesthetics. They were found to
produce similar qualitative emergence phenomena that
were quantitatively a little different. Phencyclidine
and TCP especially produced typical, similar EEG
changes with sharp waves, particularly in young
patients. All three agents were given in doses of
0.25-0.35 mg/kg i.v. (Lear et al., 1959; Scholler, Thies
and Wiemers, 1960).
More recently, Javitt and Zukin (1991) emphasized that
a number of positive and negative symptoms of
schizophrenia can be induced in normal volunteers or
drug abusers with phencyclidine. Carlsson and Carlsson
(1990) have observed in animals interactions between
glutamatergic and monoaminergic systems in the brain
that have implications for schizophrenia.
Fauman and Fauman (1981) and Burns and Lerner
(1981) reviewed in detail the drug abuse aspects and
pharmacology of phencyclidine in man. Table 2 lists the
dose-effect relationships of phencyclidine in normal or
drug abuse subjects as reported by Burns and Lerner
(1981). It should be noted that in many respects
phencyclidine ingestion or infusion in humans is a better
model of an organic brain syndrome inducing delirium
and, in sufficient dose, loss of memory and conscious-
ness. This has not been emphasized in the current
literature.
Ketamine
Ketamine is an arylcyclohexylamine derivative of
phencyclidine. It is also a non-competitive NMDA
antagonist. Lodge and his colleagues (1983) were the
first to show that ketamine, phencyclidine, related
arylcyclohexylamines and congeners were antagonists of
excitatory amino acids like aspartate and glutamate. The
early history of the development of ketamine as an
anesthetic agent is documented by McCarthy (1981).
Corssen (1990) and Dundee (1990a,b) have reviewed the
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Table 2 Dose-related effects of phencyclidine in normal subjects
From Burns and Lerner, 1981
historical introduction of ketamine into human anesthesia
and the term dissociative anesthesia (Domino, Chodoff
and Corssen, 1965; Corssen and Domino, 1966). It was
clear to all of the anesthesiologists and clinical pharma-
cologists who used ketamine that there was a need to tame
the ketamine ’tiger’. Albin, Bunegin and Garcia (1990)
have detailed the post-anesthetic emergence reactions to
ketamine involving > 12 283 different procedures in
10 861 patients. Their findings are summarized in Table 3.
0ye et al. (1991) studied the S- and R- (0.5 mg/kg i.v.)
forms of ketamine in normal volunteers. The S-form is
more potent and selective for NMDA receptor blockade
while the R-form has more sigma receptor affinity. Their
figure and legend of the ’effects of ketamine on the gates
of perception’ is reproduced herein as Fig. 1 and is
especially pertinent.
Table 3 Incidence rates for select adverse reactions in 12 183
procedures (10 861 patients) participating in 88 studies with
CI-581 (with and without those considered non-drug-attributable)
From Albin et al., 1990
Low doses of ketamine in humans do not necessarily
alter perception in a negative way. Foster et al. (1991)
gave an i.v. infusion of three different subanesthetic doses
of ketamine (0.05, 0.1 and 0.2 mg/kg/h) to six patients
with Alzheimer’s disease. The patients showed no
drowsiness and their reaction times and digit span were
unaffected by any of the doses of ketamine used.
Surprisingly, there was a dose-related improvement in
finger tapping speed, as well as improvement in the
Buschke Selective Reminding Test recall and long-term
retrieval scores. Low doses of ketamine were well
tolerated in these patients. Since NMDA receptors are
involved in brain function, including arousal and
memory, this study requires further research and
explanation because one would have predicted exactly the
opposite effects even with the small doses of ketamine
used.
Dizocilpine (MK-801)
When MK-801 was first described by Clineschmidt et al.
(1982a-c), it was viewed as a potent anticonvulsant,
central sympathomimetic with apparent anxiolytic
properties. Shortly thereafter, a young graduate student
at the University of Michigan informed this author that
MK-801 had potent phencyclidine-like effects in animals.
Rather than having an open mind to this possibility, this
author informed the young person that he was in error
because the chemical structure of MK-801 was so
different from phencyclidine. It is a lesson this old
professor will never forget, for he did not observe
the animals given MK-801 and instead relied on his
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Figure 1 Effects of ketamine on the gates of perception. A
model for the action of S-ketamine in humans. (A similar
model for R-ketamine would have to include putative sigma
receptor-mediated effects.) On increasing concentrations, S-
ketamine blocks an increasing number of NMDA receptor-
operated channels. ’The gates of perception’ are gradually
closed, resulting in analgesia and dysperceptions. Ketamine
also inhibits NMDA receptor-mediated feedback to inhibitory
centers (GABAergic) and the decreased inhibitory activity
leads to release of monoamines. Further increase of ketamine
causes the characteristic ’dissociative’ anesthesia during which
muscle tone and reflexes are maintained and circulation and
respiration are enhanced. According to this model, excitation,
dreams and hallucinations during wakening from ketamine
anesthesia are due to increased monoamine activity combined
with decreased GABAergic tone. The psychopharmacological
effects during subanesthetic (pre-anesthetic) concentrations
may mimic some of the ’negative symptoms’ in mental
disease, whereas the psychopharmacological effects during
wakening (’emergence phenomena’) also include ’positive’
(haloperidol-sensitive) symptoms. Benzodiazepines counteract
both the increase in monoamines during the period of
anesthesia and the psychotomimetic emergence phenomena.
(From Qye et al., 1991)
’knowledge’. How wrong one can be when one does not
observe a phenomenon first hand.
Iversen et al. (1988) summarized some of the
pharmacology and neuroprotective effects of MK-801 as
an NMDA antagonist as described by Kemp, Priestley
and Woodruff (1986) and Wong et al. (1986).
Unfortunately, MK-801 has not been well studied in
humans. During its early clinical trials as an anti-
convulsant, Troupin et al. (1986) used small doses of
MK-801 as a supplemental therapy in drug-resistant
epileptics. Initially the epileptic patients improved,
but surprisingly showed rapid tolerance to MK-801’s
therapeutic effect. Larger doses of MK-801 produced
significant mental side effects which were sufficient cause
to discontinue further study. Reimherr, Wood and
Wender (1986) conducted an open trial of MK-801 in a
small group of residual attention deficit disordered adults.
Some of the females had an improvement in temper,
emotional reactivity, mood and concentration but this
was not as clear in the males. A few of the patients liked
the ’beneficial’ effects of MK-801. The mental and
dysphoric effects of larger doses of MK-801 have not been
adequately studied, especially when given parenterally.
Therefore, our knowledge of the effects of dizocilpine
on human awareness is very incomplete. Stimulus
discriminative and other studies in animals indicate that
the behavioral effects of this agent are phencyclidine like
(Koek and Woods, 1988a,b).
(ib )N Allylnormetazocine
[NANM, (:f:)SKF-IO,047] ]
A remarkable literature has accumulated since Martin et
al. (1976) described the canine delirium induced with
( ± )SKF-10,047. They suggested that ( ± )SKF-10,047 is
a ligand for a sigma ’opioid’ receptor. We now know that
( - )SKF-10,047 has opioid properties and that in low
concentrations ( + )SKF-10,047 is a ligand for a non-
opioid sigma receptor and in very high concentrations a
ligand for the PCP site in the ion channel of the NMDA
receptor. Musacchio (1990) reviewed the relationship
between the psychotomimetic effects of opiates and the
sigma receptor. He concluded that the dysphoric and
psychotomimetic effects of opiates reside with the ( - )
and not the (+) enantiomers. Naloxone does not
antagonize the effects of phencyclidine and ( ± )SKF-10,047
in dogs (Vaupel, 1983). Vaupel has also shown that
( + )SKF-10,047 produces typical phencyclidine-like effects
in dogs, while ( - )SKF-10,047 is less potent. The term
sigma receptor has taken on a new meaning. A very large
literature exists on this subject (see symposia volumes by
Domino and Kamenka, 1988; Kamenka and Domino,
1992).
Keats and Telford (1964) found that (±)SKF-10,047
is dysphoric in humans. Whether ( + )SKF-10,047 is more
dysphoric than ( - )SKF-10,047 in humans is unknown.
The effects of both agents given separately on human
awareness have yet to be determined. In animal
behavioral experiments ( + )SKF-10,047 is phencyclidine-
like (Brady, Balster and May, 1982; Koek and Woods,
1988a,b) and is a NMDA antagonist (Largent, Gundlach
and Schneider, 1986).
Etoxadrol, dioxadrol and its .
enantiomers dexoxadrol and
levoxadrol
Both etoxadrol and dioxadrol are structurally different
from phencyclidine, yet they share similar pharmaco-
logical properties in animals and man. In humans,
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etoxadrol produces a dissociative anesthetic state
characterized by analgesia and amnesia, with emergence
reactions (Frederickson, Longnecker and Allen, 1976;
Wilson et al., 1970, 1973). Dioxadrol, a related
compound, has a pharmacology similar to etoxadrol. The
( + ) enantiomer of dioxadrol is dexoxadrol and the ( - )
enantiomer is levoxadrol. Jasinski, Martin and Sappira
(1968), Lasagna and Pearson (1965) and Simopoulos et
al. (1970) reported analgesic and psychotomimetic effects
with dexoxadrol in humans that are similar to those
reported with phencyclidine. Hampton et al. (1982) have
shown dexoxadrol to be a potent displacer of [ 3H ] PCP
binding in vitro in contrast to levoxadrol. Berry, Anis
and Lodge (1984) have shown that both etoxadrol and
dexoxadrol selectively antagonize NMDA relative to
quisqualate and kainate in rat spinal cord neurons
in contrast to levoxadrol. Hence, it is clear that still
another class of NMDA antagonists alter human
awareness.
Future studies
To date, almost all of the published studies in humans
have been with the non-competitive antagonists of
NMDA receptors of glutamic acid. It is clear that such
agents cause marked dissociation of human awareness,
producing in small to moderate doses altered perceptions
and mood suggestive of some of the signs and symptoms
of both schizophrenia and dementia. As more drugs are
developed that are safe to test in man and that act at
different sites in the NMDA receptor complex, it will be
possible to obtain a better appreciation of the role of one
aspect of glutamic acid function on human awareness.
Many very interesting compounds have already been
developed that act at different sites in the NMDA
complex in vivo and in vitro in animals. Future studies
of the human psychopharmacology of such compounds
will be very interesting and potentially of therapeutic
importance.
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